Biology of the pathogenic yeast Candida glabrata

Folia Microbiologica

Volumn 51, Issue 1, 2006, Pages 3-20

  Bialkova A ^a   Subik J ^a  

^a Physics and Informatics   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA GLABRATA; CANDIDIASIS; CYTOLOGY; GENETICS; HUMAN; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; PHYSIOLOGY; REVIEW;

CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, MULTIPLE, FUNGAL; HUMANS;

CANDIDA GLABRATA; EUKARYOTA; SACCHAROMYCES CEREVISIAE;

EID: 33646840455     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02931443     Document Type: Review

References (151)

1. ABRANCHES J., MORAIS P.B., ROSA C.A., MENDOCA-HAGLER L.C., HAGLER A.N.: The incidence of killer activity and extracellular proteases in tropical yeast communities. Can.J.Microbiol. 43, 328-336 (1997).
2. AHMAD S., MUSTAFA A.S., KHAN Z., AL-RIFAIY A.I., KHAN Z.U.: PCR-enzyme immunoassay of rDNA in the diagnosis of candidemia and comparison with amplicon detection by agarose gel electrophoresis. Internal.J.Med.Microbiol. 294, 45-51 (2004).
3. AISNER J., SCHIMPFF S.C., SUTHERLAND J.C., YOUNG V.M., WIERNDC P.H.: Torulopsis glabrata infections in patients with cancer. Increasing incidence and relationships. Am.J.Med. 61, 23-28 (1976).
4. ARIF S., BARKHAM T., POWER E.G., HOWELL S.H.: Techniques for investigation of an apparent outbreak of infection with Candida glabrata. J.Clin.Microbiol. 34, 2205-2209 (1996).
5. ATTFIELD P.V.: Trehalose accumulates in Saccharomyces cerevisiae during exposure to agents that induce heat shock response. FEBS Lett. 225, 259-263 (1987).
6. BARNETT J.A., PAYNE R.W., YARROW D.: Yeasts: Characteristic and Identification. Cambridge University Press, Cambridge (UK) 1983.
7. BARNS S.M., LANE D.J., SOGIN M.L., BIBEAU C., WEISBURG W.G.: Evolutionary relationship among pathogenic Candida species and relatives. J.Bacteriol. 173, 2250-2255 (1991).
8. BARRY A.L., PFALLER M.A., RENNIE R.P., FUCHS P.C., BROWN S.D.: Precision and accuracy of fluconazole susceptibility testing by broth microdilution, E-test, and disk diffusion methods. Antimicrob.Agents Chemother. 46, 1781-1784 (2002).
9. BECK-SAGUE C., JAWRIS W.R.: Secular trends in the epidemiology of nosocomial infections in the United States, 1980-1990. National nosocomial infection surveillance system. J.Infect.Dis. 167, 1247-1251 (1993).
10. BERROUANE Y.F., HERWALDT L.A., PFELLER M.A.: Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J.Clin.Microbiol. 37, 531-537 (1999).
11. BETTINA-BAUER E., WOLFGER H., KUCHLER K.: Inventory of yeast ABC proteins: about sex, stress, pleiotropic drug and heavy metal resistance. Biochim.Biophys.Acta 1461, 217-236 (1999).
12. BOUCHARA J.P., DECLERCK P., CIMON B., PLANCHENAULT C., DE GENTILE L., CHABASSE D.: Routine use of CHROMagar Candida medium for presumptive identification of Candida yeast species and detection of mixed fungal populations. Clin.Microbiol. Infectol. 2, 202-208 (1996).
13. BOUCHARA J.P., ZOUHAIR R., LE BOUDOUIL S., RENIER G., FILMON R., CHABASSE D., HALLET J.N., DEFONTAINE A.: In-vivo selection of an azole-resistant petite mutant of Candida glabrata. J.Med.Microbiol. 49, 977-984 (2000).
14. BRONDZ I., OLSEN I.: Multivariate analyses of cellular carbohydrates and fatty acids of Candida albicans, Torulopsis glabrata, and Saccharomyces cerevisiae. J.Clin.Microbiol 28, 1854-1857 (1990).
15. BUCHAILLE L., FREYDIERE A.M., GUINET R., GILLE Y.: Evaluation of six commercial systems for identification of medically important yeasts. Eur.J.Clin.Microbiol.Infect.Dis. 17, 479-488 (1998).
16. BUCHTA V., KOLÁŘ M., BERGEROVÁ T., CHMELAŘOVÁ E., MALLÁTOVÁ N., HOROVÁ B., POZLEROVÁ E., HORNÍKOVÁ M., HAMAL P., DOBIÁŠ OVÁ S.: Occurrence of potentially pathogenic yeasts in large Czech hospitals. (In Czech) Klin.Mikrobiol.Inf.Lék. 4, 10-17 (1998).
17. BUSSEY H., SKIPPER N.: Membrane-mediated killing of Saccharomyces cerevisiae by glycoproteins from Torulopsis glabrata. J.Bacteriol. 124, 476-483 (1975).
18. BUSSEY H., SKIPPER N.: Killing of Torulopsis glabrata by Saccharomyces cerevisiae killer factor. Antimicrob.Agents Chemother. 9, 352-354 (1976).
19. BUZZINI P., MARTINI A.: Large-scale screening of selected Candida maltosa, Debaryomyces hansenii and Pichia anomala killer toxin activity against pathogenic yeasts. Med.Mycol. 39, 479-482 (2001).
20. CALCAGNO A.M., BIGNELL E., WARN P., JONES M.D., DENNING D.W., MUHLSCHLEGEL F.A., ROGERS T.R., HAYENS K.: Candida glabrata STE12 is required for wild-type levels of virulence and nitrogen starvation induced filamentation. Mol.Microbiol. 50, 1309-1318 (2003).
21. CALCAGNO A.M., BIGNELL E., ROGERS T.R., CANEDO M., MUHLSCHLEGEL F.A., HAYENS K.: Candida glabrata Ste20 is involved in maintaining cell wall integrity and adaptation to hypertonic stress, and is required for wild-type levels of virulence. Yeast 21, 557-568 (2004).
22. CASTAÑO I., KAUR R., PAN S., CREGG R., DE LAS PENAS A., GUO N., BIERY M.C., CRAIG N.L., CORMACK B.P.: Tn7-based genome-wide random insertional mutagenesis of Candida glabrata. Genome Res. 13, 905-915 (2003).
23. CHEN X.J., CLARK-WALKER G.D.: The petite mutation in yeasts: 50 years on. Internat.Rev.Cytol. 194, 197-238 (2000).
24. CLARK-WALKER G.D., SRIPRAKASH K.S.: Map location of transcripts from Torulopsis glabrata mitochondrial DNA. EMBO J. 2, 1465-1472 (1983).
25. COHN M., MCEACHERN M.J., BLACKBURN E.H.: Telomeric sequence diversity within the genus Saccharomyces. Curr.Genet. 33, 83-91 (1998).
26. COIGNARD C., HURST S.F., BENJAMIN L.E., BRANDT M.E., WARNOCK D.W., MORRISON CJ.: Resolution of discrepant results for Candida species identification by using DNA probes. J.Clin.Microbiol. 42, 858-861 (2003).
27. CORMACK B.P., FALKOW S.: Efficient homologous and illegitimate recombination in the opportunistic yeast pathogen Candida glabrata. Genetics 151, 979-987 (1999).
28. CROSS E. W., PARK S., PERLIN D.S.: Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in treatment of the vaginitis. Microb.Drug Resist. 6, 155-161 (2000).
29. CSANK C., HAYENS K.: Candida glabrata displays pseudohyphal growth. FEMS Microbiol.Lett. 189, 115-120 (2000).
30. DEAN M., ALLIKMETS R., GERRARD B., STEWART C., KISTLER A., SHAFER B., MICHAELIS S., STRATHERN J.: Mapping and sequencing of two yeast genes belonging to the ATP-binding cassette superfamily. Yeast 10, 377-383 (1994).
31. DEFONTAINE A., BOUCHARA J.P., DECLERC P., PLANCHENAULT C., CHABASSE D., HALLET J.N.: in-vitro resistance to azoles associated with mitochondrial deficiency in Candida glabrata. J.Med.Microbiol. 48, 663-670 (1999).
32. DRUETTA A., FREYDIERE A., GUINET R., GILLE Y.: Evaluation of five antifugnal susceptibility testing systems. Eur.J.Clin.Microbiol. Infect.Dis. 12, 336-342 (1993).
33. DUJON B.: Altogether now - sequencing the yeast genome. Curr.Biol. 2, 279-281 (1992).
34. DUJON B., SHERMAN D., FISHER G., DURRENS P., CASAREGOLA S., LAFONTAINE I., DE MONTIGNY J., MARCK C., NEUVEGLISEN C., TALLA E., GOFFARD N., FRANGEULT L., AIGLE M., ANTHOURAD V., BABOUR A., BARBE V., BARNAY S., BLANCHIN S., BECKERICH J.M., BEYNE E., BLEYKASTEN C., BOISRAME A., BOYER J., CATTOLICO R., CONFANIOLERI F., DE DARUVAR A., DESPONS L., FABRE E., FAIRHEAD C., FERRY-DUMAZET H., GROPPI A., HANTRAYE F., HENNEQUIN C., JAUNIAUX N., JOYET P., KACHOURI R., KERREST A., KOSZUL R., LEMAIRE M., LESUR I., MA L., MULLER H., NICAUD J.M., NIKOLSKI M., OZTAS S., OZIER-KALOGEROPOULOS O., PELLENZ S., POTIER S., RICHARD G.F., STRAUB M.L., SULEAU A., SWENNEN D., TEKAIA F., WESOLOWSKI-LOUVELL M., WESTHOF E., WIRTH B., ZENIOU-MEYER M., ZIVANOVIC I., BOLOTIN-FUKUHARA M., THIERRY A., BOUCHIER C., CAUDRON B., SCARPELLI C., GAILLADIN C., WEISSENBACH J., WINCKER P., SOUCIET J.L.: Genome evolution in yeasts. Nature 430, 35-44 (2004).
35. EDLIND T., SMITH L., HENRY K., KATIYAR S., NICKELS J.: Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signaling. Mol.Microbiol. 46, 257-268 (2002).
36. EIDEN-PLACH A., ZAGORC T., HEINTEL T., CARIUS Y., BREINIG F., SCHMITT M.J.: Viral preprotoxin signal sequence allows efficient secretion of green fluorescent protein by Candida glabrata, Pichia pastoris, Saccharomyces cerevsiae, and Schizosaccharomyces pombe. Appl.Environ.Microbiol. 70, 961-966 (2004).
37. EL BARKANI A., HAVENS K., MOSCH H., FROSCH M., MUHLSCHLEGEL F.A.: Candida glabrata shuttle vector suitable for translational fusion to lacZ and use of β-galactosidase as a reporter gene expression. Gene 246, 151-155 (2000).
38. ESPINEL-INGROFF A., PFALLER M., ERWIN M.E., JONES R.N.: Interlaboratory evaluation of Å-test method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2 % glucose. J.Clin.Microbiol. 34, 848-852 (1996).
39. ESPINEL-INGROFF A., BARCHIESI F., HAZEN K.C., MARTINEZ-SUAREZ J.V., SCALISE G.: Standardization of antifungal susceptibility testing and clinical relevance. Med.Mycol. 1, 68-78 (1998).
40. FENN J.P., SEGAL H., BARLAND B., DENTON D., WHISENANT J., CHUN H., CHRISTOFFERSON K., HAMILTON L., CARROL K.: Comparison of updated Vitek Yeast Biochemical Card and API 20C Aux yeast identification systems. Clin.Microbiol. 32, 1184-1187 (1994).
41. FIDEL P.L., VAZQUEZ J.A., SOBEL J.D.: Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin.Microbiol.Rev. 12, 80-96 (1999).
42. FREYDIERE A.M., GUINET R., BOIRON P.: Yeast identification in the clinical microbiology laboratory: phenotypical methods. Med. Mycol 39, 9-33 (2001).
43. FREYDIERE A.M., PARANT F., NOEL-BARON F., CREPY M., TRENY A., RABERIN H., DAVIDSON A., ODDS F.C.: Identification of Candida glabrataby a 30-second trehalase test. J.Clin.Microbiol. 40, 3602-3605 (2002).
44. FREYDIERE A.M., ROBERT R., PLOTON C., MAROT-LEBOND A., MONERAU F., VANDENESH F.: Rapid identication of Candida glabrata with a new commercial test, Glabrata RTT. J.Clin.Microbiol. 41, 3861-3863 (2003).
45. FREYDIERE A.M., PERRY J.D., FAURE O., WILLINGER B., TORTORANO A.M., NICHOLSON A., PEMAN J., VERWEIJ P.E.: Routine use of a commercial test, Glabrata RTT, for rapid identification of Candida glabrata in six laboratories. J.Clin.Microbiol. 42, 4870-4872 (2004).
46. GANCEDO J.: Yeast carbon catabolite repression. Microbiol.Mol.Biol.Rev. 62, 334-361 (1998).
47. GEBER A., HITCHCOCK C.A., SWARTZ J.E., PULLEN F.S., MARDSEN K.E., KWON-CHUNG K.J., BENNET J.E.: Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob.Agents Chemother. 39, 2708-2717 (1995).
48. GHANNOUM M.A.: Potentional role of phospholipases in virulence and fungal pathogenesis. Clin.Microbiol.Rev. 13, 122-143 (2000).
49. GlETZ D., JEAN A.S., WOODS R., SCHLIESTL R.H.: Improved method for high efficiency transformation of intact yeast cells. Nucl.Acids Res. 20, 1425 (1992).
50. GOW N.: Candida albicans switches mates. Mol.Cell 10, 217-218 (2002).
51. HAMAL P., DOBIÁŠOVÁ S., KOCMANOVÁ I., JEDLIČKOVÁ I., LÁZNIČKOVÁ T., BUCHTA V.: Candidemia in large Czech hospitals 2000-2002: an epidemiological study. Abstr. p. 463, 15th Congr. ISHAM, San Antonio (USA) 2003.
52. HANIC-JOYCE P.J., JOYCE P.B.: A high-copy-number ADE2-beanng plasmid for transformation of Candida glabrata. Gene 211, 395-400 (1998).
53. HASENCLEVER H.F., MITCHEL W.O.: Antigenic relationships of Torulopsis glabrata and seven species of the genus Candida. J.Bacteriol 79, 677-681 (1960).
54. HAW R., YARRAGUDI A.D., UEMURA H.: Isolation of Candida glabrata homologue of RAP1, a regulator of transcription and telomere function in Saccharomyces cerevisiae. Yeast 18, 1277-1284 (2001).
55. HAZEN K.C.: New and emerging yeast pathogens. Clin.Microbiol.Rev. 8, 462-478 (1995).
56. HENDOLIN P.H., PAULIN L., KOUKILA-KAHKOLA P., ANTILLA V.J., MALMBERG H., RICHARDSON M., YLIKOSKI J.: Panfungal and multiplex liquid hybridization for detection of fungi in tissue specimens. J.Clin.Microbiol. 38, 4186-4192 (2000).
57. HENRY K.W., NICKELS J.T., EDLIND T.D.: Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob.Agents Chemother. 44, 2693-2700 (2000).
58. HICKEY W.F., SOMMERVILLE L.H., SCHOEN F.J.: Disseminated Candida glabrata: report of uniquely severe infection and a literature review. Am.J.Clin.Pathol. 80, 724-727 (1983).
59. HIMMELREICH U., SOMORJAI R.L., DOLENKO B., CHA LE O., DANIEL H.M., MURRAY R., MOUNTFORD C.E., SORREL T.C.: Rapid identification of Candida species by using nuclear magnetic resonance spectroscopy and a statistical classification strategy. Appl. Environ.Microbiol. 69, 4566-4574 (2003).
60. HITCHCOCK C.A., PYE G.W., TROKE P.P., JOHNSON E.M., WARNOCK D.W.: Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37, 1962-1965 (1993).
61. HSU M.C., CHEN K.W., LO H.J., CHEN Y.C., LIAO M.H., LIN Y.H.: Species identification of medically important fungi by use of real-time LightCycler PCR. J.Med.Microbiol. 52, 1071-1076 (2003).
62. HUANG L.U., CHEN C.H., CHOU C.F., LU J.J., CHI W.M., LEE W.H.: Rapid identification of Candida glabrata based on trehalose and sucrose assimilation using Rosco diagnostic tablets. Zhonghua Yi Xue Za Zhi (Taipei) 64, 568-574 (2001).
63. IZUMIKAWA K., KAKEYA H., TSAI H.F., GRIMBERG B., BENNET J.E.: Function of Candida glabrata ABC transporter gene, PDH1. Yeast 20, 249-261 (2003).
64. KANBE T., ARISHIMA T., HORII T., KIKUCHI A.: Improvements of PCR-based identification targeting the DNA topoisomerase II gene to determine major species of the opportunistic fungi Candida and Aspergillus fumigatus. Microbiol.Immunol. 47, 631-638 (2003).
65. KAO A.S., BRANDT M.E., PRUITT W.R., CONN L.A., PERKINS B.A., STEPHENS D.S., BAUGHMAN W.S., REINGOLD A.L., ROTHROCK G.A., PFALLER M.A., PINNER R.W., HAJJEH R.A.: The epidemiology of candidemia in two United States cities: results of population-based active surveillance. Clin.Infect.Dis. 29, 1164-1170 (1999).
66. KAUFMANN C.S., MERZ W.G.: Electrophoretic karyotypes of Torulopsis glabrata. J.Clin.Microbiol. 27, 2165-2168 (1989).
67. KAUR R., CASTANO I., CORMACK B.P.: Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob.Agents Chemother. 48, 1600-1613 (2004).
68. 5,6-desaturation. FEBS Lett. 400, 80-82 (1993).
69. KELLY S.L., LAMB D.C., CORRAN A.J., BALDWIN B.C., KELLY D.E.: Mode of action and resistance to azole antifungals associated with formation of 14α-methylergosta-8,24(28)-dien-3β,6α-diol. Biochem.Biophys.Res. Commun. 207, 910-915 (1995).
70. KITADA K., YAMAGUCHI E., ARISAWA M.: Isolation of a Candida glabrata centromere and its use in construction of plasmid vectors. Gene 175, 105-108 (1996).
71. KITADA K., YAMAGUCHI E., HAMADA K., ARISAWA M.: Structural analysis of a Candida glabrata centromere and its functional homology to the Saccharomyces cerevisiae centromere. Curr.Genet. 31, 122-127 (1997).
72. KOCKOVÁ-KRATOCHVÍLOVÁ A.: Taxonomy of Yeast and Yeast-Like Microorganisms. (In Slovak) Alfa, Bratislava 1990.
73. KONTOYANNIS O.P.: Modulation of fluconazole sensitivity by the interaction of mitochondria and Erg3p in Saccharomyces cerevisiae. J.Antimicrob.Chemother. 46, 191-197 (2000).
74. KOSZUL R., MALPERTUY A., FRANGEUL L., BOUCHIER C., WINCKER P., THIERRY A., DUTHOY S., FERRIS S., HENNEQUIN C., DUJON B.: The complete mitochondrial genome sequence of the pathogenic yeast Candida (Torulopsis) glabrata. FEBS Lett. 534, 39-48 (2003).
75. KRČMÉRY V., ORAVCOVÁ E., ŠPANÍK S., MRÁZOVÁ-STUDENÁ M., TRUPI. J., KUNOVÁ A., STOPKOVÁ-GREY K., KUKUČKOVÁ E., KRUPOVÁ I., DEMITROVIČOVÁ A., KRÁLOVIČOVÁ A.: Nosocomial breakthrough fungemia during antifungal prophylaxis or empirical antiftmgal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of etiology risk factors and outcome. J.Antimicrob.Agents. 41, 373-380 (1998).
76. KREN A., MAMNUN Y.M., BAUER B.E., SCHULLER C., WOLFGER H., HATZIXANTHIS K., MOLLAPOUR M., GREGORI C., PIPER P., KUCHLER K.: War1p, a novel transcription factor controlling weak acid stress response in yeast. Mol.Cell.Biol. 23, 1775-1785 (2003).
77. KURZMANN C.P., FELL J.W. (Eds): The Yeasts, a Taxonomic Study, 4th ed. Elsevier, Amsterdam 1998.
78. LACHKE S.A., SRIKANTHA T., TSAI L.K., DANIELS K., SOLL D.R.: Phenotypic switching in Candida glabrata involves phase-specific regulation of the metallothionein gene MT-II and the newly discovered hemolysin gene HLP. Infect.Immun. 68, 884-895 (2000).
79. LARONE D.H.: Medically Important Fungi - a Guide to Identification, 3rd ed. ASM Press, Washington (DC) 1995.
80. LAVERDIERE M., ROTSTEIN C., BOW EJ., ROBERTS R.S., IOANNOUI S., CARR D., MOGHADDAM N., Canadian Fluconazole Study Group: Impact of prophylaxis on fungal colonization and infection rates in neutropenic patients. J.Antimicrob. Chemother. 46, 1001-1008 (2000).
81. LEHMANN P.F., LIN D., LASKER B.A.: Genotypic identification and characterization of species and strains within the genus Candida by using random amplified polymorphic DNA. J.Clin.Microbiol. 30, 3249-3254 (1992).
82. LOPEZ J., DALLE F., MANTELIN P., MOIROUX P., NIERLICH A.C., PACOT A., CUISENIER B., VAGNER O., BONNIN A.: Rapid identification of Candida glabrata based on trehalose and sucrose assimilation using Rosco diagnostic tablets. J. Clin.Microbiol. 39, 1172-1174 (2001).
83. LUO G., MITCHELL T.G.: Rapid identification of pathogenic fungi directly from cultures by using multiplex PCR. J.Clin.Microbiol. 40, 2860-2865 (2002).
84. LUO G., SAMARANAYAKE L.P.: Candida glabrata, an emerging fungal pathogen, exhibits superior relative cell surface hydrophobicity and adhesion to denture acrylic surfaces compared with Candida albicans. APMIS 110, 601-610 (2002).
85. LUO G., SAMARANAYAKE L.P., CHEUNG B.P., TANG G.: Reverse transcriptase chain reaction (RT-PCR) detection of HLP gene expression in Candida glabrata and its possible role in in vitro hemolysin production. APMIS 112, 283-290 (2004).
86. MACKENZIE K.F., SINGH K.K., BROWN A.D.: Water stress plating hypersensitivity of yeast: protective role of trehalose in Saccharomyces cerevisiae. J.Gen.Microbiol. 134, 1661-1666 (1988).
87. MACREDIE I.G., CASTELLI L.A., MEHRA R.K., THORVALSEN J.L., WINGE D.R.: Heterologous gene expression and protein secretion from Candida glabrata. Biotechnol.Appl.Biochem. 19, 265-269 (1994).
88. MAIWALD M., KAPPE R., SONNTAG H.G.: Rapid presumptive identification of medically relevant yeasts to the species level by polymerase chain reaction and restriction enzyme analysis. J.Med.Vet.Mycol. 32, 115-122 (1994).
89. MAQUELIN K., CHOO-SMITH L.P., ENDTZ H.P., BRUINING H.A., PUPPELS G.J.: Rapid identification of Candida species by confocal Raman microspectroscopy. J.Clin.Microbiol. 40, 594-600 (2002).
90. MARICHAL P., VAN DEN BOSSCHE H., ODDS F.C., NOBELS G., WARNOCK D.W., TIMMERMAN V., VAN BROECKHOVEN C., FAY S., MOSE-LARSEN P.: Molecular biological characterization of an azole-resistant Candida glabrata isolate. Amtimicrob.Agents Chemother. 41, 2229-2237 (1997).
91. MARMIROLI N., TEDESHI F., SABATINI M.A., TRUZZI G., FERRARI C., PUGLISI P.P.: Relationship between growth inhibition and mitochondrial function in petite-negative yeasts - II. Effect of central nervous system drugs upon pathogenic and non-pathogenic Candida species. Biol.Cell 53, 75-79 (1985).
92. MASSONET C., VAN ELDERE J., VANEECHOUTTE M., DE BAERE T., VERHAEGEN J., LAGROU K.: Comparison of Vitek 2 with ITS2-fragment length polymorphism analysis for identification of yeast species. J.Clin.Microbiol. 42, 2209-2211 (2004).
93. MCCULLOGH M.J., CLEMONS K.V., MCCUSKER J.H., STEVENS D.A.: Intergenic transcribed spacer PCR ribotyping for differentiation of Saccharomyces species and interspecific hybrids. J.Clin.Microbiol. 36, 1035-1038 (1998).
94. MEHRA R.K., THORVALDSEN J.L., MACREADIE I.G., WINGE D.R.: Cloning system for Candida glabrata using elements from metallothionein-IIa-encoding gene that confer autonomous replication. Gene 113, 119-124 (1992).
95. MEYER S.A., AHEARN D.G., YARROW D.G.: Genus 4. Candida BERKHOUT, pp. 585-844 in N.J.W. Kreger-van Rij (Ed.): The Yeasts: a Taxonomic Study, 3rd ed. Elsevier Biomedical Press, Amsterdam 1984.
96. MIYAZAKI H., MIYAZAKI Y., GEBER A., PARKINSON T., HITCHCOCK C.H., FALKONER D.J., WARD D.J., MARDSEN K., BENNET J.E.: Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata. Antimicrob.Agents Chemother. 42, 1695-1701 (1998).
97. MOYE-ROWLEY W.S.: Transcriptional control of multidrug resistance in the yeast Saccharomyces. Progr.Nucl.Acids Res.Mol.Biol. 73, 251-279 (2003).
98. NAKAYAMA H., IZUTA M., NAGAHASHI S., SIHTA E.Y., SATO Y., YAMAZAKI T., ARISAWA M., KITADA K.: A controllable gene-expression system for the pathogenic fungus Candida glabrata. Microbiology 144, 2407-2415 (1998).
99. NAKAYAMA H., IZUTA M., NAKAYAMA N., AOKI Y.: Depletion of squalene synthase (ERG9) gene does not impair growth of Candida glabrata in mice. Antimicrob.Agents Chemother. 44, 2411-2418 (2000).
100. NAKAYAMA H., NAKAYAMA N., ARISAWA M., AOKI Y.: In vitro and in vivo effects of 14a-demethylase (ERG11) depletion in Candida glabrata. Antimicrob.Agents Chemother. 45, 3037-3045 (2001).
101. NELISSEN B., DE WACHTER R., GOFFEAU A.: Classification of all putative permeases and other membrane plurispanners of the major facilitator superfamily encoded by the complete genome of Saccharomyces cerevisiae. FEMS Microbiol.Rev. 21, 113-134 (1997).
102. NEWLON C.S.: Yeast chromosome replication and segregation. Microbiol.Rev. 52, 568-601 (1988).
103. NEWMAN S.L., FLANIGAN T.P., FISHER A., RINALDI M.G., STEIN M., VIGILANTE K.: Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin.Infect.Dis. 19, 684-686 (1994).
104. NGUYEN M.H., PEACOCK J.E., MORRIS A.J., TANNER D.C., NGUYEN M.L., SNYDMAN D.R., WAGENER M.M., RINALDI M.G., YU V.L.: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am.J. Med. 100, 617-623 (1996).
105. NIESTERS H.G., GOESSENS W.H., MEIS J.F., QUINT W.G.: Rapid, polymerase chain reaction-based identification assays for Candida species. J.Clin.Microbiol. 31, 904-910 (1993).
106. NUCCI M., COLOMBO A.L.: Emergence of resistant Candida in neutropenic patients. Braz.J.Infect.Dis. 6, 124-128 (2002).
107. O'CONNOR R.M., MCARTHUR C.R., CLARK-WALKER G.D.: Respiratory-deficient mutants of Torulopsis glabrata, a yeast with circular mitochondrial deoxyribonucleic acid of 6 μm. J.Bacteriol. 126, 959-968 (1976).
108. ODDS F.C., BERNAERTS R.: CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida. J.Clin.Microbiol. 32, 1923-1929 (1994).
109. ODDS F.C., RINALDI M.G., COOPER J.R., FOTHERGILL A., PASARELL L., MCGINNIS M.R.: Candida and Torulopsis: a blinded evaluation of use of pseudohypha formation as basis for identification of medically important yeasts. J.Clin.Microbiol. 35, 313-316 (1997).
110. ONYEWU C., BLANKENSHIP J.R., DEL POETA M., HEITMAN J.: Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors againts Candida albicans, Candida glabrata, and Candida krusei. Antimicrob.Agents Chemother. 47, 956-964 (2003).
111. PARKINSON T., FALCONER D.J., HITCHCOCK C.A.: Fluconazole resistance due to energy dependent drug efflux in Candida glabrata. Antimicrob.Agents Chemother. 39, 1696-1699 (1995).
112. PETTER R., KWON-CHUNG K.J.: Disruption of the SWF1 gene abolishes trehalose utilization in the pathogenic yeast Candida glabrata. Infect.Immun. 64, 5269-5273 (1996).
113. PFALLER M.A., MESSER S.A., HOLLIS R.J., JONES R.N., DOERN G.V., BRANDT M.E., HAJJEH R.A.: Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States, Canada, and South America. Diagn.Microbiol.Infect. 33, 217-222 (1999).
114. PFALLER M.A., DIEKAMA D.J., JONES R.N., SADER H.S., FLUIT A.C., HOLLIS R.J., MESSER S.A., Sentry Participant Group: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the Sentry antimicrobial surveillance program. J.Clin.Microbiol. 39, 3254-3259 (2001a).
115. PFALLER M.A., MESSER S.A., MILLS K., BOLMSTROM A., JONES R.N.: Evaluation of Å-test method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J.Clin.Microbiol. 39, 4387-4389 (2001b).
116. PFALLER M.A., DIEKAMA D.J., BOYKEN L., MESSER S.A., TENDOLKAR S., HOLLIS R.J.: Evaluation of the E-test and disk-diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J. Clin. Microbiol. 41, 1875-1880 (2003a).
117. PFALLER M.A., DIEKEMA D.J., MESSER S.A., BOYKEN L., HOLLIS R.J.: Activities of fluconazole and voriconazole against 1586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and E-test methods: report from the Artemis global antifungal susceptibility program, 2001. J.Clin.Microbiol. 41, 1440-1446 (2003b).
118. PFALLER M.A., MESSER S.A., BOYKEN L., RICE C., TENDOLKAR S., HOLLIS R.J., DIEKEMA D.J.: Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12796 clinical isolates of Candida spp. J.Clin.Microbiol. 42, 3137-3141 (2004).
119. PIENS M.A., PERRY J.D., RABERIN H., PARANT F., FREYDIERE A.M.: Routine system of a one-minute trehalase and maltase test for the identification of Candida glabrata in four laboratories. J.Clin.Pathol. 56, 687-689 (2003).
120. PLACKÝ R., HAMAL P., RACLAVSKÝ V.: MCRAPD as a new approach to rapid and accurate identification of pathogenic yeasts. J.Microbiol.Meth. 60, 107-113 (2005).
121. POWELL H.L., SAND C.A., RENNIE R.P.: Evaluation of CHROMagar Candida for presumptive identification of clinically important species. Diagn.Microbiol. Infect.Dis. 32, 201-204 (1998).
122. RANGEL-FRAUSTO M.S., WIBLIN T., BLUMBERG H.M., SAIMAN L., PATTERSON J., RINALDI M., PFALLER M., EDWARDS J.E., JAWRIS W., DAWSON J., WENZEL R.P.: National Epidemiology of Mycoses Survey (NEMIS): variation in rates of bloodstream infection due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin.Infect.Dis. 29, 253-258 (1999).
123. ROBERT R., NAIL S., MARLOT-LEBLOND A., COTTIN J., MIEGEVILLE M., QUENOUILLERE S., MAHAZA C., SENET J.M.: Adherence of platelets to Candida species in vivo. Infect.Immun. 68, 570-576 (2000).
124. SANDVEN P., BEVANGER L., DIGRANES A., GAUSTAD P., HAUKLAND H.H., STAINBAKK M., The Norvegian Yeast Study Group: Constant low rate of fungemia in Norway, 1991 to 1996. J.Clin.Microbiol. 36, 3455-3459 (1998).
125. SANGLARD D., ISCHER F., KOYMANS L., BILLE J.: Amino acid substitution in the cytochrome P-450 lanosterol α-demethylase (CYP51A1) from azole resistant Candida albicans clinical isolates contributes to resistance to azole antifungal agents. Antimicrob.Agents Chemother. 42, 241-253 (1998).
126. SANGLARD D., ISCHER F., CALABRESE D., MAJCHERCZYK P.A., BILLE J.: The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob.Agents Chemother. 43, 2753-2765 (1999).
127. SANGLARD D., ISCHER F., BILLE J.: Role of ATP-binding-cassette transporter gene in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob.Agents Chemother. 45, 1174-1183 (2001).
128. SCHUFFENECKER I., FREYDIERE A., DE MONTCLOS H., GILLE Y.: Evaluation of four commercial system for identification of medically important yeasts. Eur.J.Clin.Microbiol.Infect.Dis. 12, 255-260 (1993).
129. SELVARANGAN R., BUI U., LIMAYE A.P., COOKSON B.T.: Rapid identification of commonly encountered Candida species directly from blood culture bottles. J.Clin.Microbiol. 41, 5660-5664 (2003).
130. SHERMAN D., DURRENS P., BEYNE E., NIKOLSKI M., SOUCIET J.L., Génolevures Consortium: Génolevures: comparative genomics and molecular evolution of hemiascomycetous yeasts. Nucl.Acids Res. 32, D315-D318 (2004).
131. SHU H.H., MARTIN N.C.: RNase P RNA in Candida glabrata mitochondria is transcribed with substrate tRNAs. Nucl.Acids Res. 19, 6221-6226 (1991).
132. SKIPPER N., BUSSEY H.: Mode of action of yeast toxins: energy requirement for Saccharomyces cerevisiae killer toxin. J.Bacteriol. 129, 668-677 (1977).
133. SRIKANTHA T., LACHKE S.A., SOLL D.R.: Three mating type-like loci in Candida glabrata. Eukaryot.Cell 2, 328-340 (2003).
134. +-pantothenate symporter. J.Biol.Chem. 274, 18747-18752 (1999).
135. THORVALSEN J.L., MEHRA R.K., YU W., SEWELL A.K., WINGE D.R.: Analysis of copper-induced metallothionein expression using autonomously replicating plasmids in Candida glabrata. Yeast 11, 1501-1511 (1995).
136. TSAI H.F., BARD M., IZUMIKAWA K., KROL A.A., CULBERTSON N.T., PIERSON C.A., BENNET J.E.: Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension. Antimicrob.Agents Chemother. 48, 2483-2489 (2004).
137. VAN DEN BOSSCHE H., WILLEMSENS G., COOLS W., MARICHAL P., LAUWERS W.: Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem.Soc. Trans. 11, 665-667 (1983).
138. VAN DEN BOSSCHE H., MARICHAL P., ODDS F.C., LE JEUNE L., COENE M.C.: Characterization of an azole resistant Candida glabrata isolate. Antimicrob.Agents Chemother. 36, 2602-2610 (1992).
139. VARMA A., EDMAN J.C., KWON-CHUNG K.J.: Molecular and genetic analysis of URA5 transformants of Cryptococcus neoformans. Infect.Immun. 60, 1101-1108 (1992).
140. VAZQUEZ J.A., DEMBRY L.M., SANCHEZ V., VAZQUEZ M.A., SOBEL J.D., DMUCHOVSKI C., ZERVOS M.J.: Nosocomial Candida glabrata colonization: an epidemiologic study. J.Clin.Microbiol. 36, 421-426 (1998).
141. WADA S., NIIMI M., NIIMI K., HOLMES A.R., MONK B.C., CANNON R.D., UEHARA Y.: Candida glabrata ATP-binding cassette transporters Cdr1p and Pdh1p expressed in the Saccharomyces cerevisiae strain deficient in membrane transporters show phosphorylation-dependent pumping properties. J.Biol.Chem. 277, 46809-46821 (2002).
142. WEIG M., JANSCH L., GROSS U., DE KOSTER C.G., KLIS P.M., DE GROOT P.W.: Systematic identification in silica of covalently bound cell wall proteins and analysis of protein-polysaccharide linkages of the human pathogen Candida glabrata. Microbiology 150, 3129-3144 (2004).
143. WHELAN W.L., KWON-CHUNG K.J.: Parasexual genetics of Torulopsis glabrata. J.Bacteriol. 169, 4991-4994 (1987).
144. WILLINGER B., MANAFI M.: Evaluation of CHROMagar Candida for rapid screening of clinical specimens for Candida species. Mycoses 42, 61-65 (1999).
145. WILLINGER B., OBRADOVIC A., SELITSCH B., BECK-MANNAGETTA J., BUZINA W., BRAUN H., APFALTER P., HIRSCHL A.M., MAKRISTATHIS A., ROTTER M.: Detection and identification of fungi from fungus balls of the maxillary sinus by molecular techniques. J. Clin. Microbiol. 41, 581-585 (2003).
146. WILLINS D.A., SHIMER G.H., COTTAREL G.: A system for deletion and complementation of Candida glabrata genes amenable to high-throughput application. Gene 292, 141-149 (2002).
147. WINGARD J.R., MERZ W.G., RINALDI M.G., MILLER C.B., KARP J.E., SARAL R.: Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob.Agents Chemother. 37, 1847-1849 (1993).
148. WONG S., BUTLER G., WOLFE K.H.: Gene order evolution and paleopolyploidy in hemiscomycetc yeasts. Proc.Nat.Acad.Sci.USA 99, 9272-9277 (2002).
149. WONG S., FARES M.A., ZIMMERMANN W., BUTLER G., WOLFE K.H.: Evidence from comparative genomics for a complete sexual cycle in the "asexual" pathogenic yeast Candida glabrata. Genome Biol. 4, R10 (2003).
150. 14DM purified from Saccharomyces cerevisiae microsomes. Biochem.Pharmacol. 36, 229-235 (1987).
151. ZHOU P., SZCZYPKA M.S., YOUNG R., THIELE D.J.: A system for gene cloning and manipulation in the yeast Candida glabrata. Gene 142, 135-140 (1994).